Proteomic analysis of the urothelial cancer landscape

Area of Science:

• Oncology
• Proteomics
• Molecular Biology

Background:

• Urothelial bladder cancer (UC) presents a diverse biological spectrum, complicating prognosis and treatment strategies.
• Current molecular classifications often lack direct correlation with protein-level information relevant for therapy.
• Challenges exist in sample pre-analytics for comprehensive proteomic analysis.

Purpose of the Study:

• To improve pre-analytics for proteomic analysis of urothelial bladder cancer (UC) samples.
• To characterize proteomic subtypes within UC with prognostic significance.
• To identify potential therapeutic targets and predict drug efficacy based on proteomic data.

Main Methods:

• Collected and analyzed 434 urothelial bladder cancer (UC) samples (242 tumors, 192 normal mucosae).
• Performed advanced proteomic analyses to characterize tumor specificity and identify robust subtypes.
• Utilized in silico and in vitro methods for drug prediction and validation.

Main Results:

• Identified robust proteomic subtypes of UC with prognostic information independent of histopathology.
• Evaluated sample-wise tumor specificity for numerous biomarkers.
• In silico drug prediction identified compounds with potential efficacy, supported by in vitro data, indicating predictive value of proteomic clusters.

Conclusions:

• Proteomics provides crucial insights into urothelial bladder cancer (UC) biology and offers a powerful tool for personalized oncology.
• The identified proteomic subtypes and drug predictions pave the way for novel therapeutic strategies.
• Comprehensive proteomic data and tumor specificity information are now available for a significant portion of the UC proteome.